Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iotetric Acid SCHEMBL37863 | 1.00 | TSHR (0.65) | TSHRMAPK1KDM4ENPC1MAPT | |
| Iotetric Acid SCHEMBL27748028 | 1.00 | TSHR (0.65) | TSHRMAPK1KDM4ENPC1MAPT | |
| Iotroxic Acid SCHEMBL27729545 | 1.00 | TSHR (0.65) | TSHRMAPK1KDM4ENPC1MAPT | |
| Iotrizoic Acid SCHEMBL31409209 | 0.94 | TSHR (0.58) | TSHRMAPK1KDM4ENPC1MAPT | |
| Iotrizoic Acid SCHEMBL2111608 | 0.94 | TSHR (0.58) | TSHRMAPK1KDM4ENPC1MAPT | |
| Ioglycamic Acid SCHEMBL29881458 | 0.93 | TSHR (0.70) | TSHRMAPK1KDM4ENPC1MAPT | |
| Ioglycamic Acid SCHEMBL433485 | 0.93 | TSHR (0.70) | TSHRMAPK1KDM4ENPC1MAPT | |
| Iodoxamic Acid SCHEMBL377402 | 0.89 | TSHR (0.74) | TSHRMAPK1NPC1RAB9APOLB | |
| SCHEMBL12142383 | 0.89 | TSHR (0.74) | TSHRMAPK1NPC1RAB9APOLB | |
| Iodoxamic Acid SCHEMBL29397252 | 0.89 | TSHR (0.74) | TSHRMAPK1NPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021238893-A1 | EFFICIENT AND EFFECTIVE TISSUE CLEARING AGENTS AND THEIR COMPOSITIONS | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2021-12-02 | — | — | WO | claimed |
| US-20170066828-A1 | Humanized Anti-HLA-DR Antibodies | IMMUNOMEDICS, INC. | 2017-03-09 | — | — | US | claimed |
| US-20160375234-A1 | TRANSPAPILLARY METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING BREAST CONDITIONS | ATOSSA THERAPEUTICS, INC. | 2016-12-29 | — | — | US | claimed |
| EP-3092027-A1 | TRANSPAPILLARY METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING BREAST CONDITIONS | Atossa Genetics Inc. (US) | 2016-11-16 | — | — | EP | claimed |
| US-9393325-B2 | Bioabsorbable co-filler for cerebrovascular aneurysms | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2016-07-19 | — | — | US | claimed |
| US-20160151124-A1 | IMPLANTABLE MARKERS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-06-02 | — | — | US | claimed |
| EP-3019208-A1 | IMPLANTABLE MARKERS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2016-05-18 | — | — | EP | claimed |
| EP-1521775-B1 | MONOCLONAL ANTIBODY PAM4 AND ITS USE FOR DIAGNOSIS AND THERAPY OF PANCREATIC CANCER | IMMUNOMEDICS INC (US) | 2015-09-09 | — | — | EP | claimed |
| WO-2015106094-A1 | TRANSPAPILLARY METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING BREAST CONDITIONS | Atossa Genetics Inc. (US) | 2015-07-16 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-0703790-B1 | IODINATED PARAMAGNETIC CHELATES, AND THEIR USE AS CONTRAST AGENTS | BRACCO SPA (IT) | 2000-08-16 | — | — | EP | claimed |
| EP-0576740-B1 | Process and device for the preparation of a contrast medium from a concentrate | SCHERING AG (DE) | 1998-07-29 | — | — | EP | claimed |
| US-5662930-A | SURFACE MODIFICATION | THE LIPOSOME COMPANY, INC. (US) | 1997-09-02 | — | — | US | claimed |
| US-5660814-A | Iodinated paramagnetic chelates, and their use as contrast agents | DIBRA S.P.A. (IT) | 1997-08-26 | — | — | US | claimed |
| US-5614214-A | INCORPORATING LIPID, REDUCING BLOOD PRESSURE DECREASE | THE LIPOSOME COMPANY, INC. (US) | 1997-03-25 | — | — | US | claimed |
| EP-0703790-A1 | IODINATED PARAMAGNETIC CHELATES, AND THEIR USE AS CONTRAST AGENTS | BRACCO S.p.A. (IT) | 1996-04-03 | — | — | EP | claimed |
| EP-0699068-A1 | REDUCTION OF LIPOSOME-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS | THE LIPOSOME COMPANY, INC. (US) | 1996-03-06 | — | — | EP | claimed |
| US-5450847-A | Process for making doses formulation of contrast media from concentrate | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-09-19 | — | — | US | claimed |
| WO-1994027644-A1 | IODINATED PARAMAGNETIC CHELATES, AND THEIR USE AS CONTRAST AGENTS | BRACCO S.P.A. (IT) | 1994-12-08 | — | — | WO | claimed |
| WO-1994027580-A1 | REDUCTION OF LIPOSOME-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS | THE LIPOSOME COMPANY, INC. (US) | 1994-12-08 | — | — | WO | claimed |